The Endocannabinoid System and GLP-1: What the Research Actually Shows

A version of this question comes up often now that GLP-1 medications like semaglutide and tirzepatide have become part of so many patients’ lives: does cannabis help or hurt a GLP-1 drug’s effect on appetite and weight. Patients ask because the two systems both touch appetite, and because the word "endocannabinoid" and the word "incretin" have started showing up in the same research abstracts. The honest answer is more interesting than a yes or no, and it starts by correcting a direction most people assume is true.

Two systems, moving in opposite directions

The endocannabinoid system regulates appetite mainly through the CB1 receptor. When THC activates CB1, the effect on appetite is stimulating, not suppressing. That is the pharmacological basis of the "munchies," and it is well established. So if a patient is using THC-containing cannabis while on a GLP-1 medication, the direction of CB1 activation works against the appetite-suppressing effect the medication is designed to produce, not with it. Anyone hoping cannabis use would amplify a GLP-1 drug’s effect on appetite is working from the wrong mechanism entirely.

The research interest connecting these two systems runs the other way: it is about blocking or modulating CB1, not activating it, and about a separate enzyme called FAAH that controls how long the body’s own endocannabinoids stick around. Neither of those is what recreational or typical medical cannabis use does.

Ask

Common questions on this topic:⚡GLP-1 and ECS🧠Anxiety and Mood🌱GI and Gut

The rimonabant story: what blocking CB1 actually did

The clearest human evidence here is almost twenty years old, and it involves a drug that never reached long-term use. Rimonabant was a CB1 receptor antagonist, the pharmacological opposite of THC, developed specifically for weight loss and metabolic syndrome. According to PubMed, a 2008 review in the journal Drugs found that rimonabant did produce weight loss and favorable effects on components of metabolic syndrome, including the hyperglycemia seen in type 2 diabetes (Krentz et al., 2008, DOI). It worked, in the sense that blocking CB1 did what the pharmacology predicted.

It was never approved in the United States. The FDA declined approval in 2007 and asked for more safety data, specifically around depression and other psychiatric effects, and the drug was later withdrawn from the markets where it had launched. The mechanism was sound. The side-effect profile, tied to CB1’s role in the brain’s reward and mood circuitry, was not acceptable. That history is the reason CB1 blockade fell out of favor as a weight-loss strategy for more than a decade, and it is also the reason current research in this space is so cautious about anything that crosses into the brain.

Why researchers are returning to this pathway, more carefully

GLP-1 drugs have transformed obesity treatment, but they are not a complete answer. Gastrointestinal side effects, plateaus, and weight regain after stopping treatment are real, documented limitations. According to PubMed, a 2026 review in the British Journal of Pharmacology frames this directly: it describes fatty acid amide hydrolase, or FAAH, the enzyme that breaks down the body’s own endocannabinoids, as a mechanistically distinct target worth exploring alongside incretin-based therapy rather than as a replacement for it (Serra et al., 2026, DOI). FAAH controls the balance between anandamide, which the review describes as pro-appetite, and a related compound called oleoylethanolamide, which is anti-appetite and which may amplify GLP-1 secretion through separate receptor pathways. The review is explicit that human translational evidence for this approach is still limited, and that it does not propose FAAH inhibition as a standalone therapy.

The same caution shows up in newer compound design. According to PubMed, a 2023 study in the journal Obesity tested a CB1 inverse agonist called CRB-913, engineered specifically to have much lower brain penetration than rimonabant, meaning it was designed to avoid the psychiatric side effects that sank the earlier drug (Morningstar et al., 2023, DOI). In diet-induced obese mice, CRB-913 alone produced meaningful weight loss, and combining it with tirzepatide, semaglutide, or liraglutide produced larger reductions in body weight than any of those GLP-1 drugs achieved on their own in that model. This is mouse data from a pharmaceutical company’s own research program, not a human trial, and it should be read with that limitation squarely in view. What it shows is that the pharmaceutical industry’s interest in this pathway is about building new, more selective drugs, not about combining existing cannabis products with existing GLP-1 medications.

What animal studies show about combining the two systems

The preclinical picture is not uniformly tidy, and that is worth saying plainly rather than smoothing over. According to PubMed, a 2025 study in the International Journal of Molecular Sciences combined a PPAR-alpha agonist and CB1 antagonist compound with the GLP-1 drug liraglutide in rats fed a high-fat, high-fructose diet, and found the combination outperformed either compound alone at reversing diet-induced metabolic and neurological changes (de Ceglia et al., 2025, DOI). That points the same direction as the CRB-913 data: combining CB1 modulation with GLP-1 pathway drugs may do more than either alone, at least in animal models.

But a 2022 study in the same journal complicates a simple story. According to PubMed, that study gave rats the CB1 antagonist AM251 and found it reduced body fat as expected, but it also decreased circulating GLP-1 itself, along with leptin, glucagon, and ghrelin, and increased markers of systemic inflammation (O’Keefe et al., 2022, DOI). In other words, blocking CB1 did not simply add to GLP-1 signaling in that model. It changed the whole hormonal picture, including lowering the very hormone GLP-1 drugs are designed to mimic. The endocannabinoid system does not sit in isolation from the rest of appetite and metabolic signaling, and a change to one part of it can move several others at once, not always in the helpful direction.

The gut’s own appetite signals

Part of why this is complicated is that the endocannabinoid system already does double duty on hunger and fullness without any drug involved. According to PubMed, a foundational 2008 review in the Journal of Neuroendocrinology describes how the gut produces anandamide, which rises during food deprivation and acts as a hunger signal, and oleoylethanolamide, which falls during food deprivation and acts as a satiety signal, both acting on sensory nerves that carry information to the brain (Capasso and Izzo, 2008, DOI). These two closely related molecules point in opposite directions on appetite despite coming from the same biochemical family, which is a useful reminder that "the endocannabinoid system" is not one lever. It is several, and they do not all move together.

What this means if you are on a GLP-1 medication today

Nothing in this evidence supports using cannabis, in any form, to enhance a GLP-1 medication’s effect on weight or appetite. The compounds under active study, rimonabant’s successors and FAAH modulators, work by blocking or redirecting the endocannabinoid system, which is the opposite pharmacological direction from THC. If anything, regular THC use would be expected to work against appetite suppression, not with it, based on the mechanism alone. CBD is a different question: it does not activate CB1 the way THC does, and some laboratory evidence suggests it can inhibit FAAH, but that evidence has not been tested in humans in this specific context and should not be read as a reason to add CBD to a GLP-1 regimen expecting a metabolic benefit. The honest state of the science is that this is a promising area for future drug development, not a reason to change what you are doing today. If you are on a GLP-1 medication and using cannabis for any reason, the conversation worth having with your prescriber is about side effects and interactions in general, not about trying to combine the two for a metabolic effect the current evidence does not support.

Still have a question this guide did not answer?

Ask

Common questions on this topic:⚡GLP-1 and ECS🧠Anxiety and Mood🌱GI and Gut